| Literature DB >> 25207597 |
Michal Jagielski1, Johannes Wolf2, Ulrike Marzahn3, Anna Völker4, Marion Lemke5, Carola Meier6, Wolfgang Ertel7, Owen Godkin8, Stephan Arens9, Gundula Schulze-Tanzil10.
Abstract
Chondrogenic differentiated mesenchymal stromal cells (MSCs) are a promising cell source for articular cartilage repair. This study was undertaken to determine the effectiveness of two three-dimensional (3D) culture systems for chondrogenic MSC differentiation in comparison to primary chondrocytes and to assess the effect of Interleukin (IL)-10 and Tumor Necrosis Factor (TNF)α on chondrogenesis by MSCs in 3D high-density (H-D) culture. MSCs were isolated from femur spongiosa, characterized using a set of typical markers and introduced in scaffold-free H-D cultures or non-woven polyglycolic acid (PGA) scaffolds for chondrogenic differentiation. H-D cultures were stimulated with recombinant IL-10, TNFα, TNFα + IL-10 or remained untreated. Gene and protein expression of type II collagen, aggrecan, sox9 and TNFα were examined. MSCs expressed typical cell surface markers and revealed multipotency. Chondrogenic differentiated cells expressed cartilage-specific markers in both culture systems but to a lower extent when compared with articular chondrocytes. Chondrogenesis was more pronounced in PGA compared with H-D culture. IL-10 and/or TNFα did not impair the chondrogenic differentiation of MSCs. Moreover, in most of the investigated samples, despite not reaching significance level, IL-10 had a stimulatory effect on the type II collagen, aggrecan and TNFα expression when compared with the respective controls.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25207597 PMCID: PMC4200793 DOI: 10.3390/ijms150915821
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Characterization of mesenchymal stromal cells (MSCs) surface marker expression (passages 4–6) using flow cytometry. The isolated and adherent MSCs (cultured expanded for at least 4 passages) were tested for both, negative (CD3, CD4, CD8, CD14) (n = 5) and positive (CD29, CD44, CD90) markers (n = 10) using flow cytometry. The percentage of MSCs positive for the respective marker is shown (A); Less than a half of the MSCs were positive for the questionable surface marker CD106 (n = 10). The majority of the adherent MSCs was CD34 negative (n = 10) and negative for leukocyte surface proteins. The histograms of surface marker expression by MSCs of a representative donor are shown (B–B).
Figure 2Characterization of MSCs surface marker expression (passages 4–6) using fluorescence microscopy. Surface markers such as leukocyte surface proteins CD3 (A); CD4 (B); CD8 (C); CD14 (D); cell adhesion protein CD29 (E); endothelial cell marker CD34 (F,F); hyaluronan receptor CD44 (G,G); mesenchymal cell marker CD90 (H,H); and CD106 (I) are depicted by immunofluorescence microscopy (green). Cells of the human endothelial cell line PAEICKR were immunolabelled for CD34 (F), CD44 (G) and CD90 (H) as a control. Cell nuclei were counterstained using 4',6-diamidino-2-phenylindole (DAPI, blue). Scale bars = 50 µm.
Figure 3Adipogenic and osteogenic differentiated MSCs. Invert microscopical images of undifferentiated (A), adipogenic (B,D,F) and osteogenic (C,E,G) differentiated MSCs in monolayer culture. The cells were adipogenically and osteogenically differentiated for 21 days. Adipogenic differentiated cells revealed multiple fat vacuoles (B,D) which were red after oil red staining (D, arrows). Osteogenic differentiation of MSCs led to granulated elongated cells (C,E,G) which were von Kossa positive (G) and formed clusters of extracellular matrix deposits (C,G, arrows). Images of a representative experiment are shown. Scale bars = 200 µm.
Figure 4IL-10 and IL-10Rα expression in undifferentiated MSCs. Undifferentiated MSCs were cultured for at least 3 passages in monolayer culture and immunolabelled with IL-10 (A) or IL-10R (C) specific antibodies or respective isotype controls (B,D) and Alexa-488 coupled secondary antibodies (green). Cell nuclei were counterstained using DAPI (blue). A representative experiment of 4 independent tests with cells of different donors is shown. Scale bars = 50 µm.
Figure 5STAT3 and STAT1 expression in undifferentiated human MSCs. Undifferentiated MSCs were seeded (third passage) for 24 h on cover slips, serum starved and treated with 10 ng/mL recombinant IL-10 or remained untreated (control). Subsequently, the cover slips with MSCs were immunolabelled either with STAT3 (A–A) or STAT1 (B–B) specific antibodies and Alexa-Fluor®488 coupled secondary antibodies (green). As a staining control the primary antibody was omitted (C–C). Cell nuclei were counterstained using DAPI (blue). The cytoskeleton of the MSCs (also in the staining controls) is depicted using phalloidin-555 staining. A representative experiment of 2 tests with cells of 2 different donors is shown by confocal laser scanning microscopy. Scale bar = 100 µm.
Figure 6Relative gene expression of cartilage markers in H-D cultures after 14 days of differentiation and 7 days cytokine stimulation. The H-D cultures were differentiated for 14 days and stimulated during the last 7 days with either IL-10 or TNFα alone, or in combination (each 10 ng/mL). COL2A1 (A, n = 3) and ACAN (B, n = 4) encodes main structural components of articular cartilage; SOX9 (C, n = 4) encodes one of the most important transcription factors during chondrocyte differentiation, whereas TNFα (D, n = 5) encodes a pro-inflammatory cytokine; (E–E) Representative macroscopic images of the 14 day old H-D cultures after treatment. Data was normalized. (A–C) The number of experiments did not allow approving a Gaussian distribution of the data. Therefore, a Wilcoxon signed rank test was performed. p < 0.05; (D) A Gaussian distribution could be determined for the data hence one-sample-t-test, one way ANOVA and Bonferoni post test were used. n = 3–5 independent experiments with cells of different donors were performed. Co, control; (−) undifferentiated; (+) differentiated.
Figure 7Histology and type II collagen synthesis in chondrogenic differentiated MSCs under the influence of cytokines in H-D cultures. The H-D cultures were differentiated for 14 days and stimulated during the last 7 days with either IL-10 or TNFα alone, or in combination (each 10 ng/mL). HE (A–A) and alcian blue (B–B) stainings were performed; Additionally, type II collagen was immunolabelled (green, C–C). Cell nuclei were counterstained using DAPI (blue). Co, control; (−) undifferentiated; (+) differentiated. Scale bars = 100 µm (A–A and B–B), 200 µm (C–C).
Figure 8Relative gene expression of chondrogenic differentiated MSCs in H-D culture and on PGA scaffolds compared with freshly isolated, non-cultured articular chondrocytes (co).MSCs (passage 4–6) underwent chondrogenic differentiation for 14 days. (A) COL2A1; (B) ACAN; (C) SOX9. n = 3–4 independent experiments with cells of different donors were performed. Data was analyzed using the Wilcoxon signed rank test, Kruskal Wallis and Dunns post test.
Figure 9Vitality, histology and type II collagen expression of chondrogenically differentiated and undifferentiated MSCs on PGA scaffolds. Undifferentiated (−) and chondrogenically differentiated (+) MSCs were cultured in PGA. (A,A) Invert microscopical pictures (“native”) of undifferentiated and chondrogenically differentiated MSCs in PGA, (B,B) MSCs stained with FDA/PI, dead cells and PGA fibers are red and viable cells are green, (C,C) HE, (D,D) alcian blue or immunolabelled for type II collagen (E,E). In the HE and alcian blue staining the fibers and cell nuclei are stained violet. Cell nuclei were counterstained using DAPI (blue). Scale bars = 200 µm (A–B), 100 µm (C–E).
Chemical composition of used growth media.
| Stem Cell Growth Medium | Concentration |
|---|---|
| Selenium (Sigma–Aldrich, Munich, Germany) | 5 ng/mL |
| Transferrin (Sigma–Aldrich) | 5 µg/mL |
| Linoleic acid (Sigma–Aldrich) | 4.7 µg/mL |
| Insulin (Sigma–Aldrich) | 5 µg/mL |
| Ascorbic acid (Sigma–Aldrich) | 1 µg/mL |
| Dexamethasone (Sigma–Aldrich) | 1 µg/mL |
| MCDB 201 with | 34 mL/100 mL |
| Dulbecco’s modified Eagle’s medium (Biochrom AG) | 51 mL/100 mL |
| Fetal calf serum (FCS, Biochrom AG) | 15 mL/100 mL |
| Streptomycin (Biochrom AG) | 50 IU/mL |
| Penicillin (Biochrom AG) | 50 IU/mL |
| Ham’s F-12/Dulbecco’s modified Eagle’s medium supplemented with 25 μg/mL ascorbic acid (Sigma–Aldrich) | 1000 mL |
| Streptomycin (Biochrom AG) | 50 IU/mL |
| Penicillin (Biochrom AG) | 50 IU/mL |
| Amphotericin B (Biochrom AG) | 2.5 μg/mL |
| Essential amino acids (Biochrom AG) | 1 mL/100 mL |
| Fetal calf serum (Biochrom AG) | 1 mL/100 mL |
| Indomethacin (Sigma–Aldrich) | 2 µL/mL |
| Isobutyl-1-methylxanthine (Sigma–Aldrich) | 1 µL/mL |
| Rosiglitazone (Sigma–Aldrich) | 1 µL/mL |
| Insulin (Sigma–Aldrich) | 4 µL/mL |
| Dexamethasone (Sigma–Aldrich) | 1 µL/mL |
| Fetal calf serum (FCS, Biochrom AG) | 0.1 mL/mL |
| Streptomycin (Biochrom AG) | 50 IU/mL |
| Penicillin (Biochrom AG) | 50 IU/mL |
| HEPES (Biochrom AG) | 25 µL/mL |
| Dulbecco’s modified Eagle’s medium with 3.7 g/L NaHCO3 and 4.5 g/L glucose (Biochrom AG) | 10 mL |
| Dexamethasone (Sigma–Aldrich) | 1 µL/mL |
| Glycerol-3-phosphate (Sigma–Aldrich) | 10 µL/mL |
| Ascorbic acid (Sigma–Aldrich) | 2 µL/mL |
| HEPES (Biochrom AG) | 25 µL/mL |
| Streptomycin (Biochrom AG) | 50 IU/mL |
| Penicillin (Biochrom AG) | 50 IU/mL |
| 10 µL/mL | |
| HEPES (Biochrom AG) | 25 µL/mL |
| Sodium pyruvate (Sigma–Aldrich) | 10 µL/mL |
| Dexamethason (Sigma–Aldrich) | 0.1 µL/mL |
| Ascorbic acid (Sigma–Aldrich) | 1.7 µL/mL |
| Prolin (Sigma–Aldrich) | 1 µL/mL |
| ITS+1 (Sigma–Aldrich) | 10 µL/mL |
| Streptomycin (Biochrom AG) | 50 IU/mL |
| Penicillin (Biochrom AG) | 50 IU/mL |
| TGF-β1 (Pepro Tech GmbH, Hamburg, Germany) | 10 ng/mL |
| Dulbecco’s modified Eagle’s medium with 3.7 g/L NaHCO3 and 4.5 g/L glucose (Biochrom AG) | 10 mL |
Antibodies to surface markers used for flow cytometry and immunofluorescence labeling.
| Primary Antibody | Secondary Antibody |
|---|---|
| CD3, mouse anti-human CD3 (mouse IgG2a), | none |
| CD4, mouse anti-human CD 4 (mouse IgG2a), fluorescein (FITC) conjugate (Caltag) | none |
| CD8, mouse anti-human CD 8 (mouse IgG2a), fluorescein (FITC) conjugate (Caltag) | none |
| CD14, mouse anti-human CD14 antigen (mouse IgG 2a), fluorescein (FITC) conjugate (Invitrogen, Carlsbad, CA, USA) | none |
| CD29, mouse anti-human Integrin β1 monoclonal antibody (mouse IgG1) (Millipore, Billerica, MA, USA) | Donkey F(ab)2 Fragment-anti-mouse-APC (Dianova, Hamburg, Germany) |
| CD34, mouse anti-human CD34 (mouse IgG1, k), allophycocyanin (APC) conjugate (BD Pharmingen, Franklin Lakes, NJ, USA) | none |
| CD44, mouse anti-human CD 44 antibody (mouse IgG 2a) (Cell signaling, Cambridge, UK) | Donkey F(ab)2 Fragment-anti-mouse-APC (Dianova, Hamburg, Germany) |
| CD90, mouse anti-human CD90 (mouse IgG1, k), fluorescein (FITC) conjugate (BD Pharmingen) | none |
| CD106, mouse anti-human VCAM-1 monoclonal antibody (mouse IgG1) (Chemicon, Billerica, MA, USA) | Donkey F(ab)2 Fragment-anti-mouse-APC (Dianova) |
| Type II collagen, rabbit anti-human polyclonal antibody (Acris Antibodies, Herford, Germany) | Alexa-Fluor®488, donkey-anti-rabbit (Invitrogen) |
| IL-10, rabbit anti-human polyclonal antibody (tebu bio GmbH, Le-Perray-en-Yvelines, France) | Alexa-Fluor®488, donkey-anti-rabbit (Invitrogen) |
| IL-10-Receptor-α, mouse anti-human monoclonal antibody (Sigma–Aldrich) | Alexa-Fluor®488, donkey-anti-mouse (Invitrogen) |
| STAT1, rabbit anti-human monoclonal antibody (Cell Signaling) | Alexa-Fluor®488, donkey-anti-mouse (Invitrogen) |
| STAT3, rabbit anti-human monoclonal antibody (Cell Signaling) | Alexa-Fluor®488, donkey-anti-mouse (Invitrogen) |
Sequences of the primers used in the present study.
| Gene (Symbol) | NCBI Gene Reference | Length | Manufacturer |
|---|---|---|---|
| NM_001101.2 | 171 | ABI® * | |
| NM_013227.2 | 93 | ABI® * | |
| NM_000346.2 | 102 | ABI® * | |
| NM_000594.2 | 80 | ABI® * | |
| TGGGACGACATGGAGAA/GAAGGTCTCAAACATGATCTGG | 146 | Qiagen® | |
| NM_001844, NM_033150 | 142 | Qiagen® |
* ABI, Applied Biosystems® (Life Technologies™, Carlsbad, CA, USA).